Sunday, August 1, 2021

Alkaloids : General Introduction, Occurrence /Distribution, Classification, Extraction and Chemical Test

 

What are Alkaloids?

·         Alkaloids are usually secondary metabolites.

·         The term alkaloid was coined by Meissner in 1819. Alkaloids are  “alkali like” substances / organic compounds.

·         They are basic nitrogen containing compound obtained from plant, animal and microorganism having marked physiological action.

·         They are basic in nature; they contain one or more nitrogen atom (usually in heterocyclic ring).

·         First synthesized alkaloid was connine.

Define the term Alkaloids.

Alkaloids are complex organic compounds of natural or synthetic origin which are basic in nature and contains one or more nitrogen atom, normally of heterocyclic nature and possess specific pharmacological activity on human or animal body, when used in small quantity.

Discuss the distribution of Alkaloids in the plant kingdom?

·         Rare in lower plants.

·         Dicots are richer in alkaloids than Monocots.

·         Families rich in Alkaloids: Apocynaceae, Rubiaceae, Solanaceae and Papaveraceae.

·         Families free from Alkaloids: Rosaceae, Labiatae.

·         They found in different parts of the plant:

ü  All Parts e.g. Datura

ü  Barks e.g. Cinchona

ü  Seeds e.g. Nux vomica

ü  Roots e.g. Aconite

ü  Fruits e.g. Black pepper

ü  Leaves e.g. Tobacco

ü  Latex e.g. Opium

Name the different forms in which alkaloids found in Plants.

  In the form of Free bases e.g. Caffeine

  Salts with Organic acids e.g. Oxalic, Acetic acid.

  Salts with inorganic acids e.g. HCl, H2SO4

  Salts with special acids: Meconic acid in Opiumin, Quinic acid in Cinchona.

  Glycosidal form e.g. Solanine in Solanum.

Discuss the role / functions of Alkaloids in Plants.

Alkaloids are doing following functions in the plants:

  They may act as protective against insects and herbivores due to their bitterness and toxicity.

  They are, in certain cases, the final products of detoxification (waste products).

  As a source of nitrogen in case of nitrogen deficiency.

  As a Carrier: For transportation of different acids.

  They, sometimes, act as growth regulators in certain metabolic systems.

  They may be utilized as a source of energy in case of deficiency in carbon dioxide assimilation.

Explain the various physical and chemical properties of the alkaloids.

1.      Physical Properties

A. Condition:

  Most alkaloids are crystalline solids.

  Few alkaloids are amorphous solids e.g. emetine.

  Some are liquids that are either:

ü  Volatile e.g. nicotine and coniine.

ü  Non-volatile e.g. pilocarpine and hyoscine.

B. Colour:

The majority of alkaloids are colorless but some are colored e.g.: Colchicine and berberine are yellow.

Canadine is orange.

C. Solubility:

  Both alkaloidal bases and their salts are soluble in alcohol.

  Generally, the bases are soluble in organic solvents and insoluble in water

Exceptions:

ü  Bases soluble in water: caffeine, ephedrine, codeine, colchicine, pilocarpine and quaternary ammonium bases.

ü  Bases insoluble or sparingly soluble in certain organic solvents: morphine in ether, theobromine and theophylline in benzene.

Salts are usually soluble in water and, insoluble or sparingly soluble in organic solvents.

Exceptions:

ü  Salts insoluble in water: Quinine monosulphate.

ü  Salts soluble in organic solvents: Lobeline and apoatropine hydrochlorides are soluble in chloroform.

 

2.      Chemical Properties

·         Alkaloids are basic in nature (Lone pair of electrons on nitrogen)

·         Basicity increased when adjacent functional group are electron releasing.

Primary amines R-NH2 e.g. Norephedrine

Secondary amines R2-NH e.g. Ephedrine

Tertiary amines R3-N e.g. Atropine

Quaternary ammonium salts R4-N e. g. d-Tubocurarine

·         Basicity order:  R2-NH > R-NH2 > R3-N

·         Saturated hexacyclic amines are more basic than aromatic amines.

·         Bases sensitive to decomposition whereas salts are stable.

Isomerisation:

  Optically active isomers may show different physiological activities.

  l-ephedrine is 3.5 times more active than d-ephedrine.

  l-ergotamine is 3-4 times more active than d-ergotamine.

  d- Tubocurarine is more active than the corresponding l- form.

  Quinine (l-form) is antimalarial and its d- isomer quinidine is antiarrhythmic.

   The racemic (optically inactive) dl-atropine is physiologically active.

Give the general classification of Alkaloids?

There are three main types of alkaloids: (1) true alkaloids, (2) protoalkaloids, and (3) pseudoalkaloids. True alkaloids and protoalkaloids are derived from amino acids, whereas pseudoalkaloids are not derived from these compounds.



A.   True Alkaloids

 

·         True alkaloids derive from amino acid and they contain a heterocyclic ring with nitrogen.

·         These alkaloids are highly reactive substances with biological activity even in low doses.

·         All true alkaloids have a bitter taste and appear as a white solid, with the exception of nicotine which has a brown liquid.

·         True alkaloids form water-soluble salts.

·         Moreover, most of them are well-defined crystalline substances which unite with acids to form salts. True alkaloids may occur in plants (1) in the free state, (2) as salts and (3) as N-oxides.

·         These alkaloids occur in a limited number of species and families, and are those compounds in which decarboxylated amino acids are condensed with a non-nitrogenous structural moiety.

·         The primary precursors of true alkaloids are such amino acids as L-ornithine, L-lysine, L-phenylalanine/L-tyrosine, L-tryptophan and L-histidine.

·         Examples of true alkaloids include such biologically active alkaloids as cocaine, quinine, dopamine and morphine.

 

B.    Proto-alkaloids / Amino Alkaloids

 

·         Proto-alkaloids are compounds, in which the N - atom derived from an amino acid and is not a part of the heterocyclic.

·         They are derived from L-tyrosine and L-tryptophan.

·         Proto-alkaloids are those with a closed ring, being perfect but structurally simple alkaloids.

·         Examples: Ephedra, Colchicum etc.

 

C.   Pseudoalkaloids

 

·         Pseudoalkaloids are compounds, the basic carbon skeletons of which are not derived from amino acids.

·         In reality, pseudoalkaloids are connected with amino acid pathways. They are derived from the precursors or post-cursors (derivatives the in-degradation process) of amino acids.

·         They can also result from the amination and transamination reactions of the different pathways connected with precursors or post-cursors of amino acids.

·         These alkaloids can also be derived from non-amino acid precursors.

·         The N atom is inserted into the molecule at a relatively late stage, for example, in the case of steroidal or terpenoid skeletons.

·         Examples of pseudoalkaloids include such compounds as coniine, capsaicin, ephedrine, solanidine, caffeine and theobromine.

 Give the Chemical classification of Alkaloids?

Alkaloids are mainly divided into two categories on the basis of their chemical structure, that is, heterocyclic rings.

 Atypical alkaloids

 These are also known as nonheterocyclic alkaloids and contain nitrogen in aliphatic chain.



Typical alkaloids

 These are also known as heterocyclic alkaloids and contain nitrogen in heterocyclic ring system.

 






For detailed classification and structure of basic nucleus refer: https://en.wikipedia.org/wiki/Alkaloid

Discuss the classification of Alkaloids based on biosynthetic origin.

Different metabolic pathways are involved in the biosynthesis of alkaloids. It is important to know precursor / starting material from which the alkaloids in question are produced in the plant biosynthetically. It is quite convenient and also logical to group together all alkaloids having been derived from the same precursor but possessing different taxonomic distribution and pharmacological activities.

Examples

(i) Indole alkaloids derived from tryptophan.

(ii) Piperidine alkaloids derived from lysine.

(iii) Pyrrolidine alkaloids derived from ornithine.

(iv) Phenylethylamine alkaloids derived from tyrosine.

(v) Imidazole alkaloids derived from histidine.

It is, however, pertinent to mention at this juncture that the enormous volume of authentic information accumulated so far with regard to the isolation of alkaloids from a variety of plant species and their subsequent characterization by the help of latest analytical techniques they may be classified as follows:

A. Alkaloids derived from Amination Reactions

(i) Acetate-derived Alkaloids

(ii) Phenylalanine-derived Alkaloids

(iii) Terpenoid Alkaloids

(iv) Steroidal Alkaloids

B. Alkaloids derived from Anthranilic Acid

(i) Quinazoline Alkaloids

(ii) Quinoline Alkaloids

(iii) Acridine Alkaloids

C. Alkaloids derived from Histidine

Imidazole Alkaloids

D. Alkaloids derived from Lysine

(i) Piperidine Alkaloids

(ii) Quinolizidine Alkaloids

(iii) Indolizidine Alkaloids

E. Alkaloids derived from Nicotinic Acid

Pyridine Alkaloids

F. Alkaloids derived from Ornithine

(i) Pyrrolidine Alkaloids

(ii) Tropane Alkaloids

(iii) Pyrrolizidine Alkaloids

G. Alkaloids derived from Tyrosine

(i) Phenylethylamine Alkaloids

(ii) Simple Tetrahydro iso-quinoline Alkaloids

(iii) Modified Benzyl Tetrahydro iso-quinoline Alkaloids

H. Alkaloids derived from Tryptophan

(i) Simple Indole Alkaloids

(ii) Simple b-Carboline Alkaloids

(iii) Terpenoid Indole Alkaloids

(iv) Quinoline Alkaloids

(v) Pyrroloindole Alkaloids

(vi) Ergot Alkaloids

 

Discuss the classification of Alkaloids based on their major pharmacological activity.

Interestingly, the alkaloids exhibit a broad range of very specific pharmacological characteristics. Perhaps this might also be used as a strong basis for the general classification of the wide-spectrum of alkaloids derived from the plant kingdom, such as: analgesics, cardio-vascular drugs, CNS-stimulants and depressants, dilation of pupil of eye, mydriatics, anticholinergics, sympathomimetics, antimalarials, purgatives, and the like. However, such a classification is not quite common and broadly known.

Examples

(iMorphine as Narcotic analgesic;

(iiQuinine as Antimalarial;

(iiiStrychnine as Reflex excitability;

(ivLobeline as Respiratory stimulant;

(vBoldine as Choleretics and laxatives;

(viAconitine as Neuralgia;

(viiPilocarpine as Antiglaucoma agent and miotic;

(viiiErgonovine as Oxytocic;

(ixEphedrine as Bronchodilator;

(xNarceine as Analgesic (narcotic) and antitussive.

 Explain the methods of extraction of Alkaloids from crude drug material.

The extraction of alkaloids is based on their basic character and solubility profiles. Generally, alkaloids are extracted mainly using two methods.

1.    Stass-Otto Method

  • The powdered material that contains alkaloidal salts is moistened with alkaline substances like sodium bicarbon-ate, ammonia, calcium hydroxide, etc., which combines with acids, tannins and other phenolic substances and sets free the alkaloids bases. 
  • Extraction is then carried out with organic solvents such as ether or petroleum spirit. 
  • The concentrated organic liquid is then shaken with aqueous acid and allowed to separate. 
  • Alkaloid salts will be present in aqueous liquid, while many impurities remain behind in the organic liquid.

 


Manskes Method

  • The collected powdered material is extracted with water or aqueous alcohol containing dilute acid. 
  • Chloroform or other organic solvents are added and shaken to remove the pigments and other unwanted materials. 
  • The free alkaloids are then precipitated by the addition of excess alkalis like, sodium bicarbonate or ammonia and separated by filtration or by extraction with organic solvents.



Volatile liquid alkaloids (nicotine and coniine) are isolated by distillation. The powdered material that contains alkaloids is extracted with water and the aqueous extract is made alkaline with sodium carbonate or ammonia and the alkaloid is distilled off in steam. This could be collected and purified.

 Discuss the general chemical tests used for the identification of Alkaloids.

The chemical tests are performed from neutral or slightly acidic solution of drug.

 Dragendorff’s Test

 Drug solution + Dragendroff’s reagent (Potassium Bismuth Iodide), formation of Orange- red colour.

 Mayer’s Test

 Drug solution + few drops of Mayer’s reagent (potassium mercuric iodide), formation of creamy-white precipitant.

 Hager’s Test

 Drug solution + few drops of Hagers reagent (Saturated aq. Solution of Picric acid), formation of crystalline yellow precipitate.

 Wagner’s Test

 Drug solution + few drops of Wagner’s reagent (dilute Iodine solution), formulation of reddish-brown precipitate.

 Tannic Acid Test

 Drug solution + few drops of tannic acid solution, formation of buff coloured precipitate.

 Ammonia Reineckate Test

 Drug solution + slightly acidified (HCl) saturated solution of ammonia reineckate, formation of pink flocculent precipitate.

 

 

 

 

 

 

 

 

 

Thursday, July 1, 2021

INTERNATIONAL JOURNAL OF MEDICAL, PHARMACEUTICAL AND BIOLOGICAL SCIENCES (IJMPBS) LAUNCHED ITS FIRST ISSUE


INTERNATIONAL JOURNAL OF MEDICAL, PHARMACEUTICAL AND BIOLOGICAL SCIENCES (IJMPBS)

International Journal of Medical, Pharmaceutical and Biological Sciences (IJMPBS) has launched today its first issue, April-June 2021. This issue comprises of total seven article which includes one editorial article written by the editor in chief. Anjali Pawar. The abstract of the other articles is summarized below:

1. Title: NANOFIBER AND CANCER - AN OVERVIEW OF RECENT DEVELOPMENTS

Authors: Iyer Aditya Manivannan, Syed Tazib Rahaman

Abstract: Cancer is a disease of grave concern. To combat the alarming need to provide an effective treatment methodology, Nanotechnology has become a powerful tool. It aids in achieving target-specific drug delivery to the tumour site. Nanofibers are among such nano-bio materials that can encapsulate antitumor drugs. In this review we tried to enlist various commercial nano-formulations, comprehend electrospinning as a means of developing nanofibers, brief on natural, semisynthetic and synthetic polymers such as Zein, Chitin, Chitosan, Poly-lactic acid, Poly lactic-co-glycolic acid, and Polycaprolactone suitable for nanofiber preparation, and applications of Nanofibers in delivery of a single drug as well as a combination of drugs or theranostic agents in cancer. It also describes three mechanisms of drug release from nanofibers, namely, pH-responsive, thermoresponsive and magnetic-heat composite release. The review tabulates the recent developments enlightening the applications of nanofibers in cancer chemotherapy in the past two decades. Nanofibrous mats are effective systems for localized treatment involving monotherapy, combination therapy, as well as for concomitant delivery of drugs and imaging agent, or genes. They have potential applications in the prevention of post-surgical cancer recurrence. Nanocomposite systems confer the ability to modulate drug release. Systems like nanoparticles which suffer from poor circulation time can be incorporated within nanofibrous mats. With many such unforeseen advantages and merits, Nanofiber becomes a potential nanotechnology driven system that enables patient-centric therapy for grave conditions like cancer. Read more

2. Title: MORPHOLOGICAL, PHYTOCHEMICAL AND PHARMACOLOGICAL ASPECTS OF SYZIGIUM CUMINI

Authors: Anjani M. Nikhare, Wrushali A. Panchale, Amar F. Sabhadinde, Jagdish V. Manwar, Ravindra L. Bakal

Abstract: Syzygium cumini, family Myrtaceae, a medicinal plant with numerous pharmacological activities such as anti-diabetic, antioxidant, anti-hyperlipidic and hepatoprotective. Seeds are moderately rich in protein and various phytochemicals along with flavonoids quercetin and, rutin a well-known antioxidant. Its leaves are used to treat leucorrhoea, stomachache, fever, dermopathy, constipation, inhibit blood discharge in feaces and reduce radiation induced DNA damage. Jamun fruit is an effective food remedy for bleeding piles and correcting liver disorders. This will help in confirmation of traditional use along with value-added utility of plant eventually leading to higher revenues from the plant. Read more

3. Title: DEVELOPMENT AND EVALUATION OF TASTE MASKED FORMULATIONS OF FEXOFENADINE HYDROCHLORIDE

Authors: Eshani Pradeep Rane,  Meghana Babar

Abstract: Ease of administration and patient compliance is gaining significant importance in the design of dosage forms. Dysphagia (difficulty in swallowing) is a common difficulty among all age groups especially in elderly and pediatrics. Patients suffering from dysphagia show greater chances of being choked during consumption of liquid formulation. Thus, to mollify such a problem, liquid formulation of high viscosity was prepared. The objective of present research work was to design and develop pediatric taste masked formulations of Fexofenadine hydrochloride (FEH) with taste enhancement and improved bioavailability. The masking of bitter taste of the drug was a necessity to formulate it in a palatable form. Effective taste masking of Fexofenadine hydrochloride was achieved through complexation with selected cyclodextrin (2- Hydroxypropyl beta cyclodextrin/ Cavasolw7HP). Inclusion complex prepared by solid dispersion showing taste score 1 (tasteless) was selected and further subjected to in-vitro taste assessment study. Based on human panel studies, tasteless FEH-2HPBCD complex i.e., batch FE5 was selected as optimized batch and different child friendly taste masking technologies were screened for incorporation of the same. Oral flavored powder formulations were prepared by mixing drug-2HPBCD inclusion complex equivalent to 30mg of FEH with varying concentrations of sucralose and with different flavors like chocolate, lemon, cherry, pineapple, etc. Formulation batch contaning lemon flavor F4 was more acceptable to human volunteers. Effervescent granules were formulated by using different concentration of effervescent salts, sucralose and lemon flavor. Soft chewable lozenges were formulated by optimization for binder concentrations and various flavors like chocolate, cherry, lemon, pineapple, etc. Results conclusively demonstrated that successful taste masking of FEH was accomplished and that it could be formulated for oral administration with more acceptability to pediatrics and improved bioavailability. Read more

4. Title: ORALLY DISINTEGRATING FILM: AN INNOVATIVE AND EASY APPROACH

Authors: Mohd Saif Mohd Akram Momin, Neha Inayat Hussain Ansari

Abstract: Orally disintegrating film (ODF) is a novel and simple method for delivering therapeutically or medicinally active chemical substances to the body(s). The major goals of orally disintegrating films (ODFs) are to improve drug’s bioavailability, permeability, and time to action, as well as enhance patient compliance. The process of making films is identical to that of making a transdermal patch. When a film is placed in the mouth, salivary fluid causes it to disintegrate quickly, releasing the medication(s). The medication(s) will subsequently be absorbed into the bloodstream, revealing therapeutic effect. This overview covers the pros and demerits of ODF formulations, as well as formulation aspects, technologies involved in making ODF formulations, and evaluation tests conducted for the same, as well as packing and storage. Orally disintegrating film formulations are a unique dosage form designed to enhance drug delivery, therapeutic action, and patient compliance. Read more

5. Title: COVID-19 VACCINES APPROVED FOR EMERGENCY USE AND UNDER DEVELOPMENT AROUND THE GLOBE – AN OVERVIEW

Authors: Harshal Ashok Pawar, Anjali Harshal Pawar, Sandip Ashok Pawar, Prashant Ashok Pawar

Abstract: COVID-19 has caused extensive human casualties with significant economic impacts around the globe, and has imposed new challenges on health systems worldwide. When the genetic sequence of SARS-CoV-2 was revealed, global vaccine companies and scientists have stepped forward to develop a vaccine, triggering a race toward vaccine development that the whole world is relying on.  Several vaccines against SARS-CoV-2, the virus that causes COVID-19, have been developed. The first vaccines available in the US (by Pfizer-BioNTech and Moderna) are messenger RNA (mRNA) vaccines. Another mRNA vaccine is available in Europe (CureVac). Other vaccines (by Janssen-Johnson & Johnson, Astra-Zeneca, Sputnik-V, and CanSino) are made using human and primate adenovirus vectors. A third type of vaccine available outside of the US is an inactivated whole-virus SARS-CoV-2 vaccine (by Bharat Biotech, Sinopharm and Sinovac). An effective and safe vaccine could play a pivotal role in eradicating COVID-19. However, few important questions regarding SARS-CoV-2 vaccine development are explored in this review. The present review gives an insight into the current status of vaccine development and associated outcomes reported at different phases of trial. Read more

6. Title: OVERTURE IN DEVELOPMENT, PROPERTIES AND CLINICAL ASPECTS OF BIOSURFACTANTS: AN REVIEW

Authors: Ashwini H. Bijewar, Wrushali A. Panchale, Jagdish V. Manwar, Ravindra L. Bakal

Abstract: Biosurfactants are a basically assorted gathering of surface-dynamic substances created by microorganisms. They are amphiphiles, they comprise of two sections- a polar (hydrophilic) moiety and non-polar (hydrophobic) congregation. In spite of a colossal measure of examination work over the most recent twenty years on conserving the creation of biosurfactants, their business accomplishment when contrasted with their manufactured partners actually stays a financial test. Utilization of immobilized organic entity, utilization of NPs, strong state aging, coordinated aging, froth fractionation, and fill and draw method of activity could end up being other promising cycles for the upgraded modern creation of different biosurfactants. Utilization of natural, fortified waste substrates and biosurfactants coproduction with another modern efficient item should be all the more basically concentrated particularly in huge aging vessels. In present work, we have covered various physicochemical and clinical aspects of biosurfactants. Read more

The current issue of the journal is available at : https://www.aphinfo.com/ijmpbs/current-issue




Aarya Publishing House introduced new journal entitled INTERNATIONAL JOURNAL OF MEDICAL, PHARMACEUTICAL AND BIOLOGICAL SCIENCES (IJMPBS)

Aarya Publishing House (APH) is a rapidly growing academic publisher with peer-reviewed, open access journals / books covering a wide range of academic disciplines. APH was established in the year 2013 with its registered office at Kalyan (Maharashtra), India. APH was established with clear cut goal of publishing quality and noteworthy publications. APH has introduced one more new journal entitled INTERNATIONAL JOURNAL OF MEDICAL, PHARMACEUTICAL AND BIOLOGICAL SCIENCES (IJMPBS).

INTERNATIONAL JOURNAL OF MEDICAL, PHARMACEUTICAL AND BIOLOGICAL SCIENCES (IJMPBS)


International Journal of Medical, Pharmaceutical and Biological Sciences (IJMPBS) is a peer reviewed online OPEN ACCESS journal . IJMPBS is intended primarily to promote rapid publication in the fields of Medicines, Pharmaceutical, and Biological Sciences. 

IJMPBS publishes original research work that contributes significantly to further the scientific knowledge in area of Medicine, Surgery, Pharmaceutics, Novel Drug Delivery, Biopharmaceutics, Pharmacokinetics, Nanotechnology, Pharmacognosy, Phytochemistry, Natural Product Research, Pharmaceutical/Medicinal Chemistry, Computational Chemistry and Molecular Drug Design, Pharmacology and Toxicology, Pharmaceutical Analysis, Quality Control, Quality Assurance, Drug Regulatory Affair, Pharmacy Practice, Clinical and Hospital Pharmacy, Pharmacogenomics, Bioinformatics, Pharmaceutical Biotechnology, Microbiology and other related fields. 

The Journal publishes original research work either as a Full Research Paper or as a Short Communication / Case study. Review Articles on a current topic in the said fields are also considered for publication by the Journal.

APH is planning to index IJMPBS with Scopus, Google Scholar, Chemical Abstract Services (CAS), Science Central, Index Copernicus, Pharmaceutical Science Open Access Resources (PSOAR), Rubriq, Directory of Research Journals Indexing, Journal Seeker, Directory of Science, Indian Science.in, Jour Informatics, China Knowledge Research Integrated (CNKI) database and other renowned electronic databases.

The editorial team of IJMPBS is founded by distinguished members of industry and academics from various disciplines and geopolitical region. The journal follows all the international regulatory requirements in order to ensure the quality of the articles and has bright future. The first issue of the journal is released today and it contains seven articles including editorial by the editor in Chief, Anjali Pawar. For more details refer : https://www.aphinfo.com/ijmpbs  (Source of the content).


Friday, June 25, 2021

SARS-COV-2 DELTA VARIANT AND DELTA PLUS VARIANT - SYMPTOMS, TREATMENT, & VACCINE EFFICACY

 

SARS-COV-2 DELTA VARIANT AND DELTA PLUS VARIANT

Experts believe that the Delta Plus variant has increased transmissibility but it is still not very clear as to how virulent this new strain is in comparison to other variants. Medical experts say it is too early to predict the effectiveness of the existing vaccines on the new variant. A detailed study would be required to establish any effect of the mutant on the immune system.

What is SARS-CoV-2 Delta variant?

·         It is also known as lineage B.1.617.2

·         It is a variant of lineage B.1.617 of SARS-CoV-2, the virus that causes COVID-19.

·         It was first detected in India in late 2020.

·         The World Health Organization (WHO) named it the Delta variant on 31 May 2021.

·         Public Health England (PHE) and WHO classified it as a variant of concern (VOC) based on an assessment of transmissibility.

·         It showed evidence of higher transmissibility and reduced neutralization.

·         The variant is thought to be partly responsible for India's second wave of the pandemic beginning in February 2021.

·         The Delta genome has 13 mutations.

·         Don’t get confused with the delta-coronavirus which mainly affects birds.

What is Delta Plus variant?

·         The new Delta plus variant has been formed due to a mutation in the Delta or B.1.617.2 variant.

·         It is a sub-lineage of the Delta variant .

·         Delta with K417N corresponds to lineages AY.1 and AY.2 is know as Delta Plus.

·         It has been nicknamed "Nepal variant".

·         It has the K417N mutation which is also present in the Beta variant.

·         As of June 16, at least 197 cases had been found from 11 countries — Britain (36), Canada (1), India (8), Japan (15), Nepal (3), Poland (9), Portugal (22), Russia (1), Switzerland (18), Turkey (1), the United States (83), India(40 cases in Maharashtra, Kerala and Madhya Pradesh).

·         No deaths were reported among the UK and Indian cases.

What are the symptoms of Delta and Delta Plus Variants?

·         Headaches,

·         A sore throat and

·         A runny nose

·         Fever.

What is the treatment?

The treatment for those infected by the SARS-CoV-2 Delta variant is as per others infected by COVID-19.

Are Vaccines effective against new variants?

·         The WHO has said current vaccines will continue to be effective against the variant. There may be some evidence of "reduced neutralization’. 

·         A study conducted by the Public Health England, has found that both Pfizer-BioNTech and AstraZeneca-Oxford vaccines provide a 33% protection against symptomatic disease caused by the variant after the first dose. Two weeks after the second dose the Pfizer-BioNTech vaccine was found to be 88% effective at stopping symptomatic disease from the Delta variant while the AstraZeneca-Oxford vaccine was 60% effective against the variant.

·         In June 2021, Public Health England announced it had conducted a study which found that after two shots, the Pfizer-BioNTech vaccine and the AstraZeneca vaccine are respectively 96% and 92% effective at preventing hospitalisation from the Delta variant.

·         ICMR found that convalescent sera of the COVID-19 cases and recipients of Bharat Biotech's BBV152 (Covaxin) were able to neutralise VUI B.1.617 although with a lower efficacy.

·         Another study by the Centre for Cellular and Molecular Biology (CCMB) in Hyderabad found Covishield (Oxford–AstraZeneca) vaccinated sera offers protection against lineage B.1.617.

Covid-19 vaccines made by AstraZeneca and the Pfizer-BioNTec alliance remains broadly effective against Delta variant. However, it is not yet clear if the existing vaccines are effective against delta plus.

 

References:

1.       "Confirmed cases of COVID-19 variants identified in UK". www.gov.uk.

2.       "Expert reaction to cases of variant B.1.617 (the 'Indian variant') being investigated in the UK". Science Media Centre.

3.       "Covid: WHO renames UK and other variants with Greek letters". BBC News. 31 May 2021.

4.       "Confirmed cases of COVID-19 variants identified in UK". www.gov.uk. 7 May 2021.

5.       WHO labels a Covid strain in India as a 'variant of concern' — here's what we know, CNBC, 11 May 2021.

6.       "India's second COVID-19 wave", The Wire Science, 22 April 2021.

7.       The COVID-19 Delta Variant: Here's Everything You Need to Know (US publication Healthline)

8.       Yadav, PD; Sapkal, GN; Abraham, P; Ella, R; Deshpande, G; Patil, DY; et al. (7 May 2021). "Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees". Clinical Infectious Diseases. doi:10.1093/cid/ciab411. PMID 33961693

9.       "Covishield Covaxin effective against 'Indian strain' of coronavirus study suggests". The Week. Retrieved 27 April 2021.

10.   "Vaccines highly effective against hospitalisation from Delta variant". www.gov.uk. Public Health England. 14 June 2021. This article contains OGL licensed text This article incorporates text published under the British Open Government Licence v3.0:

11.   "UK study finds vaccines offer high protection against hospitalisation from Delta variant". Reuters. 14 June 2021.

 

 

Monday, June 21, 2021

US FDA Issued Form 483 to Alkem Laboratories Ltd. After Inspection of Its St Louis-based Formulation Plant

An FDA Form 483 is issued to a firm management at the conclusion of an inspection when an investigator has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic Act and related Acts.

US FDA Issued Form 483 to Alkem Laboratories Ltd.


 Alkem Laboratories Ltd., incorporated in the year 1973, is a Large Cap company (having a market cap of Rs 37,343.74 Crore) operating in Pharmaceuticals sector.

Alkem Laboratories Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra, India that manufactures and sells pharmaceutical generics, formulations and nutraceuticals in India and globally.

Alkem set up its innovative work office for ANDA improvement at Taloja in 2003. In 2006 enemy of infective medication Taxim of Alkem turned into the principal hostile to infective medication in the Indian drug industry to cross 1,000 million as far as homegrown deals in India. In 2014 Clavam other medication from Alkem crossed 2,000 million imprint as far as homegrown deals in India. In 2007 the organization recorded its first ANDA for drug Amlodipine which was endorsed in 2009. Alkem has fostered an arrangement of 705 marked conventional medications, with 13 of the brands included among the main 300 brands in India for the monetary year 2015 and an arrangement of 705 brands in India in the a half year finished 30 September 2015. Alkem have 21 assembling offices, 19 in India and 2 in US. 5 of the offices are US FDA, TGA, UK MHRA supported.

As on today, Alkem has :

  • 21 Manufacturing units
  • Over 800 brands
  • Business footprint in over 50 countries
  • A 14,500 plus strong workforce
  • Multiple acquisitions and joint ventures
  • Consolidated revenue at Rs. 83,444 million in FY2019-20
Alkem, which has operations spread across multiple territories abroad, produces a complete range of formulations of controlled substances at its finished dosage manufacturing facility in St Louis, Missouri. The US-FDA had conducted an inspection of the company's manufacturing plant at St Louis, USA from June 14-18, 2021.

At the end of the investigation, the company received Form 483 with two observations from the US-FDA. It notifies the company's management of objectionable conditions at the facility.

A FDA Form 483 is given to a firm administration at the end of an inspection when an US FDA auditor has noticed any conditions that in their judgment may establish infringement of the Food Drug and Cosmetic Act and related Acts.

The company shall submit to USFDA within the stipulated timeline, a detailed response to close out all the observations associated with this inspection.


Friday, June 18, 2021

Career Opportunity With Genericart Medicine Pvt. Ltd. - Start Your Own Franchisee / Company outlet / Join As A Pharmacist

 About Genericart Medicines Pvt. Ltd.

Genericart Medicines Pvt. Ltd. is at the top of Generic Medicine store, PAN India with ISO 9001:2015, engaged in appointing franchisee of Generic Medicine shops all over India. It has more than 1200 registered stores under Swast Aushadhi Seva / Genericart Medicines Pvt. Ltd. across seven states. The aim of the company is to open more than 25000 stores across India and give the best possible service to people.

Job / Business Opportunities with Genericart Medicines Pvt. Ltd.

Company has generated 10,000 employment through the franchise model directly or indirectly. In the coming year the company is planning to establish its own stores across PAN INDIA. We invite experienced people from sales to boost the business. We have more than 700 openings for District Head business profiles and we require more than 1000 pharmacists from different states.

Franchise Model

Genericart Medicines Pvt. Ltd. offers different franchise model:

COCO (Company Operated Company Owned) - If you have a space and want to start business with us. Here company will establish all the shops on their own and will make you a partner in business.

FOCO (Franchisee Owned Company Operated) - If you want to become a business partner with us then you can opt this model. Here the entire investment is done by the shop owner and the shop will be managed by the company or shop owner can invest half amount and half will be done by the company. All management will be done by the company on profit sharing.

FOFO (Franchisee Owned Franchisee Operated) - This is the best model where the entire setup, investment and management is done by the shop owner. All training will be provided by the company. As well as the company will provide on field support for shop owners.



What are the requirement for Franchisee ?

Investment - You should be able to invest 8 to 10 lakh rupees with expandable capital of Rs 3 to 4 lakhRequired - 1 or 2 pharmacistSpace - Minimum space of 150 sq feet ( Basement or semi basement not allowed)Location - Should be on main road of the city or market place etc.100% Documentation & Licensing - As per FDA Guidelines

To apply for Franchisee & More Details Contact: 

ROHINI VIBHUTE, District  Head, Thane.

Contact No. 9819257872

While booking franchise what will you check....

1.No. 1 organization-

2. Experience - Almost 10 years

3. Highest shops in market 

4. Highest product range 

5. Content name product

6. special products available with us

7. HIV/CANCER products/ Insulin - We have. ✅

8. Free Trasport ✅

9. Bill to bill 1 month credit ✅

10.Bill cash discount ✅

11. Online portal/ Stock ✅

12. Software backup✅

13. Quality control report ✅

14. Franchise referral schemes ✅

15. Support and training from heads/directors ✅

16. Mobile application ✅

17. Contest for shops owner✅

18. Good margins✅

Upcoming things-

19. New addition products

Online training video - sale booster.

20. Upgraded online sales support. 

Just you name it....we have everything

Job Opportunities 

Genericart Medicine Pvt. Ltd. is highering Sr. Pharmacist & Pharmacist at its various outlets in Thane Dist.


To apply for Job Contact: 

ROHINI VIBHUTE, District  Head, Thane.

Contact No. 9819257872

Thursday, June 17, 2021

A POST COVID-19 INFECTION: BLACK FUNGUS (MUCORMYCOSIS)

 

                       

Recently, several cases of mucormycosis in people with COVID-19 have been increasingly reported world-wide, in particular from India. The primary reason that appears to be facilitating Mucorales spores to germinate in people with COVID-19 is an ideal environment of low oxygen (hypoxia), high glucose (diabetes, new-onset hyperglycemia, steroid-induced hyperglycemia), acidic medium (metabolic acidosis, diabetic ketoacidosis [DKA]), high iron levels (increased ferritins) and decreased phagocytic activity of white blood cells (WBC) due to immunosuppression (SARS-CoV-2 mediated, steroid-mediated or background comorbidities) coupled with several other shared risk factors including prolonged hospitalization with or without mechanical ventilators.

The Indian government reported that more than 11,700 people were receiving care for mucormycosis as of 25 May 2021. Many Indian media outlets called it "black fungus" because of the black discoloration of dead and dying tissue the fungus causes. Even before the COVID-19 pandemic, rates of mucormycosis in India were estimated to be about 70 times higher than in the rest of the world. Due to its rapidly growing number of cases many Indian state governments have declared it an epidemic.

Mucormycosis (previously called zygomycosis) is a serious but rare fungal infection caused by a group of molds called mucormycetes. These molds live throughout the environment. Mucormycosis mainly affects people who have health problems, weak immunity or take medicines that lower the body’s ability to fight germs and sickness. It most commonly affects the sinuses or the lungs after inhaling fungal spores from the air. It can also occur on the skin after a cut, burn, or other type of skin injury.

Immunocompromising conditions are the main risk factor for mucormycosis. Patients with uncontrolled diabetes mellitus, especially those with ketoacidosis, are at high risk.

Doctors believe mucormycosis, which has an overall mortality rate of 50%, may be being triggered by the use of steroids, a life-saving treatment for severe and critically ill Covid-19 patients.

Steroids reduce inflammation in the lungs for Covid-19 and appear to help stop some of the damage that can happen when the body's immune system goes into overdrive to fight off coronavirus. But they also reduce immunity and push up blood sugar levels in both diabetics and non-diabetic Covid-19 patients. It's thought that this drop in immunity could be triggering these cases of mucormycosis.

 SIGNS AND SYMPTOMS OF MUCORMYCOSIS

Signs and indications of Mucormycosis rely upon the area in the body of the infection. Infection normally starts in the mouth or nose and enters the focal sensory system through the eyes.

In the event that the contagious contamination starts in the nose or sinus and reaches out to mind, side effects and signs may incorporate uneven eye torment or migraine, and might be joined by torment in the face, deadness, fever, loss of smell, a hindered nose or runny nose. The individual may seem to have sinusitis. The face may look swollen on one side, with quickly advancing "dark sores" across the nose or upper within mouth. One eye may look swollen and swelling, and vision might be blurred.

The symptoms of mucormycosis depend on where in the body the fungus is growing.  Contact your healthcare provider if you have symptoms that you think are related to mucormycosis.

Symptoms of rhinocerebral (sinus and brain) mucormycosis include:

  • One-sided facial swelling
  • Headache
  • Nasal or sinus congestion
  • Black lesions on nasal bridge or upper inside of mouth that quickly become more severe
  • Fever

Symptoms of pulmonary (lung) mucormycosis include:

  • Fever
  • Cough
  • Chest pain
  • Shortness of breath

Cutaneous (skin) mucormycosis can look like blisters or ulcers, and the infected area may turn black. Other symptoms include pain, warmth, excessive redness, or swelling around a wound.

Symptoms of gastrointestinal mucormycosis include:

  • Abdominal pain
  • Nausea and vomiting
  • Gastrointestinal bleeding

Disseminated mucormycosis typically occurs in people who are already sick from other medical conditions, so it can be difficult to know which symptoms are related to mucormycosis. Patients with disseminated infection in the brain can develop mental status changes or coma.

TESTING OF MUCORMYCOSIS

  • Healthcare providers consider your medical history, symptoms, physical examinations, and laboratory tests when diagnosing mucormycosis. 
  • Healthcare providers who suspect that you have mucormycosis in your lungs or sinuses might collect a sample of fluid from your respiratory system to send to a laboratory. 
  • Your healthcare provider may perform a tissue biopsy, in which a small sample of affected tissue is analyzed in a laboratory for evidence of mucormycosis under a microscope or in a fungal culture. 
  • You may also need imaging tests such as a CT scan of your lungs, sinuses, or other parts of your body, depending on the location of the suspected infection. 
  • There are no specific blood tests to detect mucormycosis.

TREATMENT OF MUCOURMYCOSIS

Treatment involves a combination of antifungal drugs, surgically removing infecting tissue and correcting underlying medical problems such as diabetic ketoacidosis.

Medicines

Intravenous bag for antifungal medicine, usually Amphotericin B, Posaconazole, or Isavuconazole. Mucormycosis is a serious infection and needs to be treated with prescription antifungal medicine, usually Amphotericin B, Posaconazole, or Isavuconazole. These medicines are given through a vein (Amphotericin B, Posaconazole, Isavuconazole) or by mouth (Posaconazole, Isavuconazole). Other medicines, including fluconazole, voriconazole, and echinocandins, do not work against fungi that cause mucormycosis.

Surgery

Often, mucormycosis requires surgery to cut away the infected tissue. Surgery can be very drastic, and in some cases of disease involving the nasal cavity and the brain, removal of infected brain tissue may be required. Removal of the palate, nasal cavity, or eye structures can be very disfiguring. Sometimes more than one operation is required.

The prognosis (outcomes) of mucormycosis infections range from fair to poor; there is about a 50% death rate that rises to about 85% for rhinocerebral and GI infections.

WAYS TO PROTECT / PREVENT FROMMUCORMYCOSIS

It’s difficult to avoid breathing in fungal spores because the fungi that cause mucormycosis are common in the environment. There is no vaccine to prevent mucormycosis. For people who have weakened immune systems, there may be some ways to lower the chances of developing mucormycosis.

A)     Protect yourself from the environment

It’s important to note that although these actions are recommended, they haven’t been proven to prevent mucormycosis.

o    Try to avoid areas with a lot of dust like construction or excavation sites. If you can’t avoid these areas, wear an N95 respirator (a type of face mask) while you’re there. 

o    Avoid direct contact with water-damaged buildings and flood water after hurricanes and natural disasters.

o    Avoid activities that involve close contact to soil or dust, such as yard work or gardening. If this isn’t possible,

o    Wear shoes, long pants, and a long-sleeved shirt when doing outdoor activities such as gardening, yard work, or visiting wooded areas.

o    Wear gloves when handling materials such as soil, moss, or manure.

o    To reduce the chances of developing a skin infection, clean skin injuries well with soap and water, especially if they have been exposed to soil or dust.

B)      Antifungal medication

If you are at high risk for developing mucormycosis (for example, if you’ve had an organ transplant or a stem cell transplant), your healthcare provider may prescribe medication to prevent mucormycosis and other mold infections. Doctors and scientists are still learning about which transplant patients are at highest risk and how to best prevent fungal infections.

CONCLUSION

Mucormycosis isn’t contagious, so you can’t get it from an infected person. Self-care measures are the best way to prevent this type of infection. If you have a weakened immune system, it’s important to keep yourself safe outdoors. Wearing a mask while doing yardwork and bandaging all wounds until they heal will help prevent fungal infections.

You may also consider taking extra precautions during the summer and autumn months, when there’s an increased amount of the fungi in the environment. Preventive measures include wearing a face mask in dusty areas, washing hands, avoiding direct contact with water-damaged buildings, and protecting skin, feet, and hands where there is exposure to soil or manure such as gardening or certain outdoor work. In high-risk groups such as organ transplant, antifungal drugs may be given as a preventative.

REFERENCES

·         Lewis RE, Kontoyiannis DP. Epidemiology and treatment of mucormycosisexternal icon. Future Microbiol. 2013 Sep;8(9):1163-75.

·         Spellberg B, Edwards Jr. J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and managementexternal icon. Clin Microbiol Rev. 2005 Jul;18(3):556-69.

·         Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human diseaseexternal icon. Clin Microbiol Rev 2000; 13:236-301.

·         Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported casesexternal icon. Clin Infect Dis. 2005 Sep 1;41(5):634-53.

·         Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosisexternal icon. Clin Infect Dis. 2012 Feb;54 Suppl 1:S23-34.

·         Walsh TJ, Gamaletsou MN, McGinnis MR, Hayden RT, Kontoyiannis DP. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis)external icon. Clin Infect Dis. 2012 Feb;54 Suppl 1:S55-60.

·         Avery RK, Michaels MG. Strategies for safe living after solid organ transplantationexternal icon. Am J Transplant. 2013 Mar;13 Suppl 4:304-10.

·         CDC. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep. 2000 Oct;49(RR-10):1-125, CE1-7.

·         Davies BW, Smith JM, Hink EM, Durairaj VD. Increased incidence of rhino-orbital-cerebral mucormycosis after Colorado floodingexternal icon. Ophthalmic Plast Reconstr Surg. 2017 May;33(3S Suppl 1):S148-S151.

·         Brizendine KD, Vishin S, Baddley JW. Antifungal prophylaxis in solid organ transplant recipientsexternal icon. Expert Rev Anti Infect Ther. 2011 May;9(5):571-81.

·         Rogers TR, Slavin MA, Donnelly JP. Antifungal prophylaxis during treatment for haematological malignancies: are we there yet? external iconBr J Haemato. 2011 Jun;153(6):681-97.